Insider Buying: Lyell Immunopharma, Inc. (NASDAQ:LYEL) Director Buys 35,640 Shares of Stock

Lyell Immunopharma, Inc. (NASDAQ:LYEL) Director Otis W. Brawley purchased 35,640 shares of Lyell Immunopharma stock in a transaction that occurred on Monday, March 31st. The shares were bought at an average price of $0.56 per share, for a total transaction of $19,958.40. Following the transaction, the director now owns 35,640 shares in the company, valued at $19,958.40. This represents a ? increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.

Lyell Immunopharma Stock Performance

Lyell Immunopharma stock traded up $0.02 during trading hours on Wednesday, reaching $0.51. 453,376 shares of the company’s stock traded hands, compared to its average volume of 1,055,784. The firm has a market capitalization of $149.83 million, a price-to-earnings ratio of -0.64 and a beta of -0.41. The firm’s 50 day moving average is $0.61 and its 200-day moving average is $0.85. Lyell Immunopharma, Inc. has a fifty-two week low of $0.48 and a fifty-two week high of $3.15.

Lyell Immunopharma (NASDAQ:LYEL) last released its earnings results on Wednesday, March 12th. The company reported ($0.72) EPS for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.52). The business had revenue of $0.01 million for the quarter. Lyell Immunopharma had a negative return on equity of 34.64% and a negative net margin of 323,792.09%. Analysts predict that Lyell Immunopharma, Inc. will post -0.78 EPS for the current year.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reissued a “neutral” rating and issued a $1.00 target price on shares of Lyell Immunopharma in a research note on Thursday, March 13th.

Hedge Funds Weigh In On Lyell Immunopharma

Institutional investors have recently modified their holdings of the stock. Decheng Capital LLC acquired a new stake in shares of Lyell Immunopharma in the 4th quarter valued at approximately $7,622,000. Foresite Capital Management V LLC acquired a new stake in Lyell Immunopharma in the fourth quarter worth $5,205,000. venBio Partners LLC acquired a new position in shares of Lyell Immunopharma in the 4th quarter valued at $4,545,000. Renaissance Technologies LLC increased its position in shares of Lyell Immunopharma by 716.7% in the 4th quarter. Renaissance Technologies LLC now owns 1,612,146 shares of the company’s stock valued at $1,032,000 after buying an additional 1,414,746 shares in the last quarter. Finally, Jacobs Levy Equity Management Inc. bought a new stake in shares of Lyell Immunopharma in the 4th quarter valued at $887,000. 66.05% of the stock is currently owned by institutional investors and hedge funds.

About Lyell Immunopharma

Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.